Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
CST-2140 by CuraSen Therapeutics for Orthostatic Hypotension: Likelihood of Approval
CST-2140 is under clinical development by CuraSen Therapeutics and currently in Phase I for Orthostatic Hypotension. According to GlobalData, Phase...